Canaccord Genuity Maintains Buy on AbbVie, Raises Price Target to $282

آبفي

AbbVie, Inc.

ABBV

0.00

Canaccord Genuity analyst Gary Nachman maintains AbbVie (NYSE: ABBV) with a Buy and raises the price target from $273 to $282.